What are the Benefits and Risks of Targeting PD-L1?
Targeting PD-L1 with immune checkpoint inhibitors has revolutionized cancer therapy, offering significant benefits, including prolonged survival and durable responses in patients with advanced cancers. However, these treatments are not without risks. Potential side effects include immune-related adverse events, such as colitis, pneumonitis, and hepatitis, which stem from increased immune system activity against normal tissues.
